Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CTX-8371 |
Synonyms | |
Therapy Description |
CTX-8371 is a tetravalent bispecific antibody that targets CD274 (PD-L1) and PDCD1 (PD-1), potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 38379869). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CTX-8371 | CTX 8371|CTX8371 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | CTX-8371 is a tetravalent bispecific antibody that targets CD274 (PD-L1) and PDCD1 (PD-1), potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 38379869). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | colon cancer | sensitive | CTX-8371 | Preclinical | Actionable | In a preclinical study, CTX-8371 treatment resulted in greater tumor growth inhibition than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) in a syngeneic mouse model of colon cancer expressing CD274 (PD-L1), with tumor regression in 62.5% (5/8) of the treated mouse models (PMID: 38379869). | 38379869 |
CD274 positive | melanoma | sensitive | CTX-8371 | Preclinical | Actionable | In a preclinical study, CTX-8371 treatment resulted in fewer lung metastases than either Keytruda (pembrolizumab) or Tecentriq (atezolizumab) monotherapy in a syngeneic mouse model of melanoma expressing CD274 (PD-L1) (PMID: 38379869). | 38379869 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |